Kangjie Medical Shareholder Cao Guigen Reduces Stake by 1.5 Million Shares, Holding Ratio Drops to 8.19%

This article is sourced from: Wabei Net

Digbei Network November 22nd, Kangjie Medical (430521) shareholder Cao Guigen reduced his holdings by 1.5 million shares through competitive trading on the stock transfer system on November 19, 2021. After the equity change, his shareholding ratio was 8.19%.

According to Wabei Network, on November 19, 2021, shareholder Cao Guigen completed the sale of 1.5 million shares through competitive bidding on the China SME Share Transfer System. Before the equity change, Cao Guigen held 11.16% of the shares, and after the equity change, the shareholding ratio was 8.19%.

It is reported that this change of equity does not involve relevant agreements, administrative transfers or changes, court rulings, or other such documents.

The company's semi-annual report for 2021 shows that the net profit attributable to the shareholders of the listed company in the first half of 2021 was 6,787,561.80 yuan, an increase of 246.86% compared to the same period last year.

According to the information disclosed on Digbei.com, Kangjie Medical is engaged in the field of optometry and ophthalmology. It is a high-tech enterprise integrating R&D, production, and sales. The company mainly produces slit lamp microscopes, slit lamp image processing systems, direct ophthalmoscopes, streak retinoscopes, fundus cameras, corneal topographers, tonometers, and other products. It has obtained 43 self-developed patents, including 9 invention patents. The company also owns 13 software copyrights. Relying on its technological advantages, it provides customers with high-quality digital integrated ophthalmic diagnostic equipment, remote diagnosis systems, and big data management platforms.